We are live on !
Find out more
AgomAb Therapeutics NV
AGMB
AGMB
About: AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
Employees: 62
News
Positive
Neutral
Negative
Sentiment
3-Months
Positive
30%
Neutral
70%
Negative
0%
Price charts implemented using Lightweight Charts™